Lakewood-Amedex Biotherapeutics Inc.
LABT Nasdaq
SEC CIK 2079272
Follow Lakewood-Amedex Biotherapeutics
Weekly email: filings, results
Net income
−$1.5M
+22.7% vs same quarter last year
EPS, diluted
−$0.62
+82.1% vs same quarter last year
Operating cash flow
−$1.3M
−106.7% vs same quarter last year
Operating income
−$1.5M
+19.7% vs same quarter last year
Source: SEC XBRL filings · latest filing